CTLA4 and hepatocellular carcinoma: As a universal way of immunotherapy, ICB treatment has made conducive progress, which aims to facilitate immune surveillance and target specific immune checkpoints, such as PD-L1 and CTLA4, which are widely used for HCC therapy [52].